RSSProceedings

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

| February 1, 2017 | 0 Comments

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes, BSc, PhD, FSS, CPsychol, FBPsS; and Philip D. Harvey, PhD Dr. Posner is with Pfizer Inc., New York, New York; Drs. Curiel, Loewenstein, and Harvey […]

Continue Reading

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

| February 1, 2016 | 2 Comments

by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS—David Daniel, MD; Amir Kalali, MD; Mark West; David Walling, PhD; Dana Hilt, MD; Nina Engelhardt, PhD; Larry Alphs, MD, PhD; Antony Loebel, MD; Kim Vanover, PhD; Sarah Atkinson, MD; Mark Opler, PhD, MPH; Gary Sachs, MD; Kari Nations, PhD; and Chris Brady, PsyD Dr. Daniel […]

Continue Reading

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium

| April 20, 2015 | 0 Comments

by Jared W. Young, PhD; William Z. Potter, MD, PhD; Steve Riley, PharmD, PhD; Geert J. Groeneveld, MD, PhD; Bruce J. Kinon, MD; Mike F. Egan, MD; and Douglas E. Feltner, MD Dr. Young is with the Department of Psychiatry, University of California San Diego, La Jolla, California, and Research Service, VA San Diego Healthcare […]

Continue Reading

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

| June 1, 2013 | 0 Comments

by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE Ms. Severe is a research consultant in Rockville, Maryland, and Dr. Stemhagen is with United Biosource Corp. in Bethesda, Maryland. Innov Clin Neurosci. 2013;10(5–6 Suppl A):29S–31S

Continue Reading